<DOC>
	<DOCNO>NCT01264367</DOCNO>
	<brief_summary>A study evaluate efficacy safety clevudine peg-interferon sequence compare clevudine alone patient HBeAg ( + ) chronic Hepatitis B clevudine peg-interferon sequential treatment patient chronic Hepatitis B HBeAg ( + )</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Clevudine Peg-interferon Sequence Compared With Clevudine Alone Patients With HBeAg ( + ) Chronic Hepatitis B Clevudine Peg-interferon Sequential Treatment Patients With Chronic Hepatitis B Who Have HBeAg ( + )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<criteria>1 . Patient 18~60 year 2 . Patient HBV DNA positive DNA level ≥ 5 x 10^5 copies/mL within 30 day baseline . 3 . Patient document HBsAg positive &gt; 6 month Patient HBeAg positive . 4 . Patient ALT level &gt; =80IU/L , prothrombin time ( INR ) &lt; 1.7 serum albumin level least 3.5 g/dL . 5 . Patient hemoglobin level &gt; =11.5g/dl ( woman ) &gt; =12.5g/dl ( man ) 6 . Women childbearing potential must negative urine pregnancy test ( βHCG ) take within 14 day start therapy . 7 . Patient able give write informed consent prior study start comply study requirement . 1 . Patient currently receive antiviral , immunomodulatory , cytotoxic corticosteroid therapy . 2 . Patients previously treat interferon , peginterferon , clevudine , lamivudine , adefovir , entecavir , telbivudine , tenofovir investigational nucleoside HBV infection . 3 . Patient coinfected HCV HIV . 4 . Patient clinical evidence decompensated liver disease HCC 5 . Patient WBC level &lt; 3.0x10^9/L 6 . Patient Platelets level &lt; 90x10^9/L 7 . Patient alpha fetoprotein level &gt; 100ng/mL 8 . Patient history Thyroid disease . 9 . Patient history autoimmune hepatitis . 10 . Patient pregnant breastfeeding . 11 . Patient unwilling use `` effective '' method contraception study 3 month use study drug cease . 12 . Patient clinically relevant history abuse alcohol drug . 13 . Patient significant immunocompromised , gastrointestinal , renal , hematological , psychiatric , bronchopulmonary , biliary disease exclude asymptomatic GB stone , neurological , cardiac , oncologic allergic disease medical illness investigator 's opinion might interfere therapy . The patient benign tumor , exclude judge investigator continuation study would interfere tumor . 14 . Patient creatinine clearance le 60mL/min estimate follow formula : ( 140age year ) ( body weight [ kg ] ) / ( 72 ) ( serum creatinine [ mg/dL ] ) [ Note : multiply estimate 0.85 woman ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>